{"gene":"CUL2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1997,"finding":"CUL2 (Hs-CUL-2) specifically associates with the trimeric pVHL-Elongin B-Elongin C (VBC) complex both in vitro and in vivo; this association is strictly dependent on the integrity of the trimeric VBC complex, and ~70% of cancer-predisposing VHL mutations disrupt this interaction. CUL2 is a cytosolic protein that can be translocated to the nucleus by pVHL.","method":"Co-immunoprecipitation in vivo and in vitro binding assays; immunofluorescence for localization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP in vivo and in vitro, multiple VHL mutants tested, replicated by subsequent studies","pmids":["9122164"],"is_preprint":false},{"year":1998,"finding":"pVHL binds to human CUL2 via Elongin C; pVHL-CUL2 complexes exist in native cells, and pVHL mutants unable to bind Elongin C/CUL2 are likewise unable to inhibit accumulation of hypoxia-inducible mRNAs under normoxia, placing CUL2 in the VHL ubiquitin ligase pathway controlling HIF target gene expression.","method":"Co-immunoprecipitation; chromatographic co-purification; functional assays with VHL mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus chromatographic co-purification plus functional mutant analysis, replicated across labs","pmids":["9447969"],"is_preprint":false},{"year":1999,"finding":"The Cul2/Rbx1 module (alongside Cdc53/Rbx1 of SCF) activates ubiquitin conjugation to target proteins via E2 enzymes Cdc34 and Ubc5, and also activates conjugation of the ubiquitin-like protein Rub1 to Cul2 itself via the dedicated E2 Ubc12; Rbx1 is the common component mediating both ubiquitin and Rub1 modification.","method":"In vitro ubiquitination and Rub1-conjugation assays with reconstituted Cul2/Rbx1 module","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay demonstrating enzymatic activity, multiple substrates and E2 enzymes tested in a single rigorous study","pmids":["10579999"],"is_preprint":false},{"year":1999,"finding":"In C. elegans, cul-2 is required at two distinct cell-cycle points: the G1-to-S-phase transition and mitotic chromosome condensation. Loss of cul-2 causes G1 arrest correlating with accumulation of the CDK inhibitor CKI-1, and prevents mitotic chromosome condensation, leading to unequal DNA segregation and chromosome bridging.","method":"Genetic loss-of-function (cul-2 mutants) in C. elegans with cell-cycle phenotype readouts; CKI-1 protein level analysis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined cellular phenotypes and molecular correlate (CKI-1 accumulation), replicated in subsequent C. elegans work","pmids":["10587644"],"is_preprint":false},{"year":2004,"finding":"VHL-box proteins (containing a BC box plus a downstream Cul2 box) specifically interact with Cul2-Rbx1, whereas SOCS-box proteins (BC box plus Cul5 box) interact with Cul5-Rbx2. Domain-swapping analyses showed Cul2 and Cul5 box sequences determine this specificity. RNAi knockdown of Cul2-Rbx1 inhibited VHL-mediated degradation of HIF-2α, while knockdown of Cul5-Rbx2 did not.","method":"Co-immunoprecipitation of endogenous complexes; domain-swap mutagenesis; RNAi knockdown with HIF-2α degradation readout","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis, Co-IP, and RNAi functional assay in a single study; defines molecular determinant of Cul2 vs. Cul5 specificity","pmids":["15601820"],"is_preprint":false},{"year":2004,"finding":"ZYG-11 and CUL-2 promote the metaphase-to-anaphase transition and M phase exit at meiosis II in C. elegans by acting together in a CUL-2-based E3 ligase; loss of either gene causes accumulation of cyclin CYB-3, delayed meiotic exit, and inverted embryonic polarity (PAR proteins, P granules, pronuclear migration).","method":"RNAi loss-of-function in C. elegans; analysis of cyclin B levels, PAR protein localization, cell-cycle progression","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with molecular substrate (CYB-3) and polarity readouts, replicated in parallel study (PMID:15215209)","pmids":["15215208","15215209"],"is_preprint":false},{"year":2004,"finding":"CUL-2 is required for degradation of cyclin B1 during C. elegans meiosis; loss of cul-2 delays or abolishes meiotic anaphase II (not anaphase I) without preventing cohesin REC-8 removal or sister chromatid separation, indicating a specific defect in chromosome movement. Partial rescue of meiotic delay by cyclin B1 inactivation confirms cyclin B1 is a CUL-2 target.","method":"Genetic loss-of-function with epistasis (cul-2 mutant × cyclin B1 inactivation); cytological analysis of chromosome behavior and REC-8 localization","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with substrate-level rescue, parallel independent study (PMID:15215208)","pmids":["15215209"],"is_preprint":false},{"year":2006,"finding":"NEDD8 modification (neddylation) of Cul2 is required for activation of the ECV (ElonginBC-Cul2-VHL) E3 ubiquitin ligase. Oxygen-dependent recognition of HIFα by VHL triggers Rbx1-dependent neddylation of Cul2, which preferentially engages the E2 ubiquitin-conjugating enzyme UbcH5a to ubiquitylate HIFα.","method":"Cell-based assays; manipulation of neddylation pathway; identification of E2 preference by biochemical assays","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based assay with mechanistic follow-up, single lab, two orthogonal approaches","pmids":["17132228"],"is_preprint":false},{"year":2007,"finding":"In C. elegans, CUL-2-based ubiquitin ligase containing FEM-1 (substrate-recognition subunit), FEM-2, and FEM-3 (cofactors) degrades the Gli-family transcription factor TRA-1 to regulate sex determination. CUL-2 physically associates with FEM-1 and TRA-1 in vivo; when FEM proteins are expressed in human cells, they interact with human CUL2 and induce proteasome-dependent TRA-1 degradation.","method":"Co-immunoprecipitation in vivo; genetic epistasis; proteasome inhibitor experiments; heterologous expression in human cells","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, and cross-species functional validation in a single rigorous study","pmids":["17609115"],"is_preprint":false},{"year":2007,"finding":"ZYG-11 is the substrate-recognition subunit for a CUL-2-based E3 ubiquitin ligase complex in C. elegans; ZYG-11 interacts with CUL-2 in vivo and binds the adaptor protein Elongin C via a nematode variant of the VHL-box motif. Members of the ZYG11 gene family across metazoa (including humans) are conserved CUL2-based ubiquitin ligase components.","method":"Co-immunoprecipitation in vivo; sequence/domain analysis; conservation mapping","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP in vivo plus domain analysis, single lab","pmids":["17304241"],"is_preprint":false},{"year":2008,"finding":"CUL-2/FEM-1 ubiquitin ligase (CBC(FEM-1)) regulates PAR-6 protein levels in C. elegans; PAR-6 physically interacts with FEM-1, and CUL-2 is required for degradation of PAR-6 to control cell polarity.","method":"Genetic epistasis (nos-3; par-2 suppression); Co-immunoprecipitation (PAR-6 with FEM-1); protein level analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis combined with Co-IP, single lab","pmids":["18502413"],"is_preprint":false},{"year":2008,"finding":"CUL2 characterization of Cul2-box sequences: the spacing between BC-box and Cullin-box is flexible (3 to ~80 aa); the LPPhiP motif conserved in most Cul5-boxes is also compatible with Cul2 interaction; residues conserved in the Cul2-box are a subset of those conserved in the Cul5-box. These structure-function studies define the rules for assembly of BC-box proteins with Cul2-Rbx1 versus Cul5-Rbx2 modules.","method":"Purification of BC-box protein complexes; structure-function/mutagenesis analysis; mass spectrometry-based interactome","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — biochemical reconstitution combined with mutagenesis, single lab","pmids":["18187417"],"is_preprint":false},{"year":2008,"finding":"CUL2 is required for HIF transcriptional activity in a manner distinct from its known role in HIFα degradation: CUL2 siRNA inhibits HIFα-mediated VEGF promoter activation and reduces ARNT expression; ectopic ARNT rescues HIF activity, placing CUL2 upstream of ARNT. In VHL-null cells (786-O), Cul2 siRNA still suppresses ARNT and VEGF, indicating this function is VHL-independent. In zebrafish, zCul2 morpholino blocks embryonic vasculogenesis.","method":"siRNA knockdown with VEGF promoter reporter assay; Western blot for ARNT; zebrafish morpholino knockdown with vasculogenesis readout","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi loss-of-function with multiple readouts (reporter assay, protein levels, in vivo vasculogenesis), single lab","pmids":["18372249"],"is_preprint":false},{"year":2011,"finding":"PRAME (preferentially expressed antigen of melanoma) is a substrate-recognition subunit of a Cul2-based E3 ubiquitin ligase. PRAME can be recruited to DNA in vitro and is specifically enriched genome-wide at transcriptionally active NFY-bound promoters and enhancers.","method":"Protein complex purification (affinity purification/mass spectrometry); chromatin immunoprecipitation (genome-wide); in vitro DNA binding","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — AP-MS identification plus ChIP-seq, single lab, two orthogonal methods","pmids":["21822215"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of VHL bound to the Cul2 N-terminal domain, Elongin B, and Elongin C reveals that Cul2 interacts with both the VHL BC box and cullin box and a novel EloC site. Cullin selectivity is influenced by distinct electrostatic interactions between cullin and substrate receptor.","method":"X-ray crystallography; comparative structural analysis with other cullin E3 ligase structures","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with structural comparison defining molecular basis of cullin selectivity, single lab but rigorous structural method","pmids":["25661653"],"is_preprint":false},{"year":2016,"finding":"CUL2 E3 ubiquitin ligase (with VHL as substrate-binding component) recognizes misfolded/fragmented TDP-43 at Glu246 in RRM2 and mediates its degradation. Excess VHL paradoxically stabilizes TDP-43 and promotes inclusion formation at the juxtanuclear protein quality control center. CUL2 also ubiquitylates mutant SOD1.","method":"Recombinant protein structural fragility assay; site-directed identification of VHL recognition residue (Glu246); cell-based overexpression/knockdown; immunohistochemistry of ALS spinal cord","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant protein assay plus cell-based mechanistic study, single lab, multiple substrates","pmids":["26751167"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the full pentameric CRL2VHL complex (Cul2-Rbx1-EloB-EloC-pVHL) reveals a closed conformation of full-length Cul2 and a new Rbx1 pose in trajectory from closed to open. Hotspot residues at the Cul2/pVHL-EloBC interface are characterized; mutations at specific positions create a selectivity switch between Cul2 and Cul5 recognition.","method":"X-ray crystallography; thermodynamic binding analyses (ITC/SPR); mutagenesis of selectivity determinants","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus biophysical binding thermodynamics plus mutagenesis in one rigorous study","pmids":["28591624"],"is_preprint":false},{"year":2021,"finding":"CUL2LRR1 ubiquitin ligase is required for ubiquitylation of the CMG helicase MCM7 subunit during S-phase in mammalian cells, leading to replisome disassembly by the p97 ATPase. A second mitotic pathway of CMG disassembly is dependent on the TRAIP ubiquitin ligase.","method":"Loss-of-function studies in mouse embryonic stem cells; ubiquitylation assays; chromatin fractionation","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with defined molecular phenotype (MCM7 ubiquitylation, replisome disassembly) in mammalian cells, rigorous controls","pmids":["33590678"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of FEM1A, FEM1B, and FEM1C (substrate adapters of CRL2) in complex with Arg/C-degron-bearing substrates reveal the molecular mechanism of C-terminal arginine degron recognition. FEM1A/C and FEM1B selectively target distinct subclasses of Arg/C-degrons, providing the structural basis for substrate selectivity in CRL2FEM1 complexes.","method":"X-ray crystallography; in vitro binding assays; global protein stability (GPS) analysis","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with multiple FEM1 paralogs plus binding assays plus functional proteome-wide GPS analysis in one study","pmids":["33398168"],"is_preprint":false},{"year":2021,"finding":"Functional recombinant CUL2·RBX1 complex purified from E. coli is enzymatically active in transferring ubiquitin (and ubiquitin-like proteins) to substrates in vitro and can bind substrate receptor modules (e.g., VHL-EloBC for HIF1α ubiquitination).","method":"Recombinant protein expression/purification; in vitro ubiquitination assay; substrate receptor binding assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of enzymatic activity, methodological paper, single lab","pmids":["34045610"],"is_preprint":false},{"year":2022,"finding":"NLRC5 recruits CUL2 to catalyze K48-linked poly-ubiquitination of the dengue virus NS3 protease domain, targeting NS3 for selective autophagic degradation via the cargo receptor TOLLIP, thereby restricting DENV infection.","method":"Co-immunoprecipitation; ubiquitination assays (K48-linkage specific); NLRC5/CUL2 knockdown/knockout with viral replication readout; autophagy flux assays","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination linkage analysis plus loss-of-function, single lab, multiple orthogonal methods","pmids":["36126167"],"is_preprint":false},{"year":2022,"finding":"Drosophila Cul2 mediates ubiquitination of Bam (bag-of-marbles) protein at multiple lysine residues in its C-terminal region, promoting Bam turnover; genetic evidence shows Cul2-mediated Bam ubiquitination is essential for germline stem cell maintenance and proper germ cell differentiation.","method":"Ubiquitination assays; genetic epistasis in Drosophila; site-directed mutagenesis of Bam lysine residues","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo ubiquitination assay plus genetic epistasis in Drosophila, single lab","pmids":["36423673"],"is_preprint":false},{"year":2024,"finding":"PRAMEL7 associates with CUL2 and recruits it to chromatin; PRAMEL7-CUL2 targets NuRD complex components for proteasomal degradation, decreasing NuRD stability and its promoter association, thereby antagonizing NuRD-mediated repression of pluripotency genes and establishing ground-state pluripotency.","method":"Co-immunoprecipitation; chromatin fractionation; proteasome inhibitor experiments; loss-of-function rescue assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, chromatin fractionation, and functional rescue, single lab, multiple orthogonal methods","pmids":["38332149"],"is_preprint":false},{"year":2025,"finding":"USP37 deubiquitylase binds the CMG helicase (via CDC45) at replication forks and counteracts CUL2LRR1-mediated ubiquitylation of CMG, preventing premature replisome disassembly. Structure-guided mutations displacing USP37 from CMG sensitize cells to DNA synthesis defects; depletion of CUL2LRR1 suppresses this sensitivity.","method":"Co-immunoprecipitation (USP37–CMG); structure-guided mutagenesis; genetic epistasis (USP37 mutant × CUL2LRR1 depletion); DNA damage sensitivity assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, structure-guided mutagenesis, and genetic epistasis in a single rigorous study","pmids":["40411782"],"is_preprint":false},{"year":2025,"finding":"CUL2 mediates K48-linked ubiquitination of Sirt2, targeting it for proteasomal degradation; silencing CUL2 stabilizes Sirt2 protein levels, reduces NF-κB pathway activation, and preserves lung epithelial barrier protein expression (Occludin, Claudin-1, ZO-1) during S. aureus infection.","method":"Co-immunoprecipitation; ubiquitination linkage assay (K48-specific); CUL2 siRNA knockdown with Sirt2 protein level and NF-κB readouts; Western blot and immunofluorescence","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ubiquitination assay plus functional knockdown, single lab, single study","pmids":["41932528"],"is_preprint":false},{"year":2025,"finding":"CUL2 competes with NRF2 for KEAP1 binding, preventing KEAP1-mediated NRF2 degradation and promoting NRF2 nuclear translocation; this CUL2-NRF2 axis suppresses ferroptosis and confers gemcitabine resistance in pancreatic cancer cells and xenografts.","method":"Co-immunoprecipitation; subcellular fractionation; proteasome inhibitor (MG132) assay; gain- and loss-of-function in vitro and xenograft studies; ferroptosis assays","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, fractionation, and functional rescue studies in vitro and in vivo, single lab","pmids":["41402811"],"is_preprint":false}],"current_model":"CUL2 is the scaffold protein of a family of multisubunit Cullin-RING E3 ubiquitin ligases (CRL2s) in which it bridges Rbx1 (the RING-H2 catalytic subunit) to an Elongin B/C adaptor linked to variable substrate-recognition subunits (VHL, PRAME, FEM1A/B/C, LRR1, ZYG-11, PRAMEL7, and others) that determine substrate specificity; the NEDD8 modification of CUL2 by Rbx1 activates ubiquitin transfer, and substrate-receptor specificity for CUL2 versus CUL5 is encoded in short 'Cul2-box' or 'Cul5-box' sequences downstream of the BC-box, as defined structurally and by mutagenesis; functionally, CRL2s ubiquitylate substrates including HIF-1/2α (targeting them for oxygen-dependent proteasomal degradation), cyclin B1 (controlling meiotic progression), CMG-MCM7 (driving replisome disassembly at termination, counteracted by USP37), TRA-1 (sex determination in C. elegans), PAR-6 (cell polarity), misfolded TDP-43, dengue NS3, Sirt2, and NuRD components, positioning CUL2 as a central regulator of cell-cycle progression, embryonic polarity, DNA replication termination, hypoxia response, and proteostasis."},"narrative":{"mechanistic_narrative":"CUL2 is the scaffold subunit of a family of multisubunit Cullin-RING E3 ubiquitin ligases (CRL2s) that direct substrate-specific ubiquitylation across cell-cycle control, hypoxia signaling, DNA replication, and proteostasis [PMID:9122164, PMID:15601820, PMID:33590678]. It bridges the catalytic RING subunit Rbx1 to an Elongin B/Elongin C adaptor, which in turn docks variable substrate-recognition subunits via a BC box plus a downstream 'Cul2 box'; domain-swap and structural analyses establish that these short Cul2-box versus Cul5-box determinants encode whether a receptor assembles with Cul2-Rbx1 or Cul5-Rbx2 [PMID:15601820, PMID:18187417, PMID:25661653, PMID:28591624]. The reconstituted Cul2/Rbx1 module is enzymatically active, conjugating ubiquitin to substrates through E2 enzymes and accepting NEDD8/Rub1 modification on Cul2 itself; this neddylation is required to activate the assembled ligase for substrate ubiquitylation [PMID:10579999, PMID:17132228, PMID:34045610]. Through the VHL substrate receptor, CRL2 targets HIF-α for oxygen-dependent proteasomal degradation, and disruption of the Cul2-VHL interaction accounts for a large fraction of cancer-predisposing VHL mutations [PMID:9122164, PMID:9447969, PMID:15601820]. Distinct substrate receptors route CUL2 to functionally diverse targets: ZYG-11 and FEM-1 direct degradation of cyclin B1, the sex-determining factor TRA-1, and the polarity protein PAR-6 to govern meiotic progression, sex determination, and embryonic polarity [PMID:15215208, PMID:15215209, PMID:17609115, PMID:18502413]; LRR1 directs ubiquitylation of the CMG helicase subunit MCM7 to drive replisome disassembly at replication termination, a reaction opposed by the deubiquitylase USP37 [PMID:33590678, PMID:40411782]; and FEM1 paralogs recognize C-terminal arginine (Arg/C) degrons [PMID:33398168]. Additional receptor-defined activities include PRAME- and PRAMEL7-directed chromatin functions that regulate transcription and pluripotency, and degradation of misfolded TDP-43, viral dengue NS3, and Sirt2 [PMID:21822215, PMID:38332149, PMID:26751167, PMID:36126167, PMID:41932528].","teleology":[{"year":1997,"claim":"Established CUL2 as a physical component of the VHL tumor-suppressor complex, linking a cullin to human cancer predisposition for the first time.","evidence":"in vivo and in vitro Co-IP showing trimeric VBC-dependent association, with disease-mutant analysis","pmids":["9122164"],"confidence":"High","gaps":["Did not define the enzymatic output of the complex","Did not identify substrates"]},{"year":1998,"claim":"Placed CUL2 functionally in the VHL ubiquitin ligase pathway controlling hypoxia-inducible gene expression by mapping the pVHL-CUL2 bridge through Elongin C.","evidence":"Co-IP, chromatographic co-purification, and VHL mutant functional assays in native cells","pmids":["9447969"],"confidence":"High","gaps":["Direct ubiquitylation of HIF substrate not yet demonstrated","Did not address oxygen-sensing mechanism"]},{"year":1999,"claim":"Demonstrated that the Cul2/Rbx1 module is an active ubiquitin-conjugating machine and is itself modified by the ubiquitin-like protein Rub1, defining its enzymatic core.","evidence":"in vitro reconstituted ubiquitination and Rub1-conjugation assays with multiple E2 enzymes","pmids":["10579999"],"confidence":"High","gaps":["Physiological substrates not identified in this assay","Role of neddylation in activation not yet shown"]},{"year":1999,"claim":"Connected CUL2 to in vivo cell-cycle control, showing it acts at the G1/S transition and in mitotic chromosome condensation via CDK-inhibitor turnover.","evidence":"C. elegans cul-2 loss-of-function with cell-cycle phenotypes and CKI-1 protein-level readout","pmids":["10587644"],"confidence":"High","gaps":["Did not establish CKI-1 as a direct ubiquitylation substrate","Substrate receptor for cell-cycle role unidentified"]},{"year":2004,"claim":"Defined the molecular code for cullin selectivity, showing Cul2-box versus Cul5-box sequences determine whether a BC-box receptor assembles with Cul2-Rbx1 or Cul5-Rbx2, with functional consequences for HIF-2α degradation.","evidence":"endogenous Co-IP, domain-swap mutagenesis, and RNAi with HIF-2α degradation readout","pmids":["15601820"],"confidence":"High","gaps":["Structural basis of box recognition not yet resolved","Did not catalog the full receptor repertoire"]},{"year":2004,"claim":"Identified ZYG-11 as a CUL-2 substrate receptor driving meiotic cyclin B turnover and showed CUL-2 controls meiotic exit and embryonic polarity, expanding its substrate range beyond HIF.","evidence":"C. elegans RNAi with cyclin B (CYB-3) levels, PAR-protein localization, and epistasis including cyclin B1 inactivation rescue","pmids":["15215208","15215209"],"confidence":"High","gaps":["Direct ubiquitylation of cyclin B by CUL-2 not biochemically reconstituted","Mammalian conservation of this meiotic role untested"]},{"year":2006,"claim":"Showed that NEDD8 modification of Cul2 activates the ECV ligase and that HIFα recognition triggers Rbx1-dependent neddylation and a specific E2 (UbcH5a) for substrate ubiquitylation, defining the activation switch.","evidence":"cell-based neddylation pathway manipulation and biochemical E2-preference assays","pmids":["17132228"],"confidence":"Medium","gaps":["Single-lab study","Quantitative kinetics of neddylation-coupled activation not established"]},{"year":2007,"claim":"Established CUL-2 substrate receptors FEM-1 and ZYG-11 as the specificity determinants targeting the Gli factor TRA-1 for sex determination, with cross-species validation in human cells.","evidence":"Co-IP, genetic epistasis, proteasome inhibition, and heterologous expression in human cells; VHL-box motif mapping for ZYG-11","pmids":["17609115","17304241"],"confidence":"High","gaps":["Human orthologous substrate of ZYG11/FEM not identified","Direct ubiquitylation site on TRA-1 not mapped"]},{"year":2008,"claim":"Extended CRL2 receptor logic with detailed Cul2-box assembly rules and revealed a VHL-independent CUL2 role supporting HIF transcriptional activity through ARNT and vasculogenesis.","evidence":"biochemical complex purification with mutagenesis; siRNA with VEGF reporter, ARNT Westerns, and zebrafish morpholino vasculogenesis assay; PAR-6 Co-IP and epistasis","pmids":["18187417","18372249","18502413"],"confidence":"Medium","gaps":["Mechanism by which CUL2 controls ARNT levels unresolved","Single-lab findings for the VHL-independent transcriptional role"]},{"year":2011,"claim":"Identified PRAME as a CUL2 substrate receptor with chromatin-targeting capacity, linking the ligase to transcriptional regulation at active promoters.","evidence":"affinity purification/mass spectrometry, genome-wide ChIP, and in vitro DNA binding","pmids":["21822215"],"confidence":"Medium","gaps":["Chromatin-associated ubiquitylation substrate of PRAME-CUL2 not defined","Single-lab study"]},{"year":2015,"claim":"Provided the first structural view of how Cul2 engages VHL-EloBC, revealing BC-box, cullin-box, and a novel EloC contact site and electrostatic determinants of cullin selectivity.","evidence":"X-ray crystallography of the Cul2 N-terminal domain with VHL-EloB-EloC and comparative analysis","pmids":["25661653"],"confidence":"High","gaps":["Full-length cullin conformation not captured","Catalytic geometry with Rbx1 and substrate not visualized"]},{"year":2017,"claim":"Resolved the full pentameric CRL2VHL architecture, capturing a closed Cul2 conformation and an intermediate Rbx1 pose, and pinpointed interface hotspots that act as a Cul2/Cul5 selectivity switch.","evidence":"X-ray crystallography with ITC/SPR binding thermodynamics and selectivity-determinant mutagenesis","pmids":["28591624"],"confidence":"High","gaps":["Dynamics of the closed-to-open transition during catalysis not directly observed","Substrate-bound ubiquitin-transfer state not resolved"]},{"year":2021,"claim":"Defined CUL2LRR1 as the S-phase ligase that ubiquitylates the CMG subunit MCM7 to drive p97-mediated replisome disassembly at replication termination, distinct from a mitotic TRAIP pathway.","evidence":"loss-of-function in mouse ES cells, ubiquitylation assays, and chromatin fractionation","pmids":["33590678"],"confidence":"High","gaps":["Trigger that activates CUL2LRR1 at termination not fully defined","Regulatory coupling to other termination factors unresolved"]},{"year":2021,"claim":"Established the structural basis of Arg/C-degron recognition by FEM1 paralog substrate adapters, defining how CRL2FEM1 complexes achieve degron-class selectivity, and confirmed in vitro enzymatic activity of recombinant Cul2-Rbx1.","evidence":"crystal structures of FEM1A/B/C with degron substrates plus GPS proteome-wide analysis; recombinant Cul2-Rbx1 ubiquitination assays","pmids":["33398168","34045610"],"confidence":"High","gaps":["Endogenous physiological Arg/C-degron substrates for each FEM1 paralog incompletely cataloged"]},{"year":2022,"claim":"Broadened CUL2 function into antiviral immunity and germline differentiation through ubiquitylation of dengue NS3 and Drosophila Bam.","evidence":"Co-IP, K48-linkage ubiquitination assays, and loss-of-function with viral replication readouts; Drosophila genetic epistasis with Bam lysine mutagenesis","pmids":["36126167","36423673"],"confidence":"Medium","gaps":["Substrate receptor mediating NS3 and Bam recognition not fully defined","Single-lab findings"]},{"year":2024,"claim":"Identified PRAMEL7 as a CUL2 receptor that degrades NuRD components to antagonize repression of pluripotency genes, linking CUL2 to ground-state pluripotency.","evidence":"Co-IP, chromatin fractionation, proteasome inhibition, and loss-of-function rescue","pmids":["38332149"],"confidence":"Medium","gaps":["Direct ubiquitylation sites on NuRD subunits not mapped","Single-lab study"]},{"year":2025,"claim":"Refined replication-termination control by showing USP37 deubiquitylates CMG to oppose CUL2LRR1 and prevent premature replisome disassembly, and added Sirt2 and a KEAP1-NRF2 axis to the CUL2 repertoire in infection and cancer.","evidence":"USP37-CMG Co-IP, structure-guided mutagenesis, and CUL2LRR1-depletion epistasis; K48 ubiquitination and knockdown assays for Sirt2; Co-IP, fractionation, and ferroptosis/xenograft assays for NRF2","pmids":["40411782","41932528","41402811"],"confidence":"High","gaps":["Whether the KEAP1-NRF2 competition reflects ligase activity or non-catalytic sequestration not resolved","Substrate receptors for Sirt2 degradation not identified"]},{"year":null,"claim":"The full mammalian substrate-receptor repertoire and the in vivo physiological substrate set for many human CRL2 complexes (e.g., ZYG11, PRAME) remain to be comprehensively defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Human orthologous substrates for several non-VHL receptors uncharacterized","Regulation of receptor exchange on the shared Cul2 scaffold not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,7,17,19,20,24]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[2,4,18,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,14,16]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[14,16,17]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,13,22]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[13,22]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,7,19]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,4,12]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[17,23]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,5,6]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,10,22]}],"complexes":["CRL2 (Cullin2-RING E3 ubiquitin ligase)","CRL2-VHL (ElonginBC-Cul2-VHL / ECV)","CRL2-LRR1","CRL2-FEM1"],"partners":["RBX1","VHL","ELONGIN C (TCEB1)","ELONGIN B (TCEB2)","ZYG-11","FEM-1","LRR1","PRAME"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13617","full_name":"Cullin-2","aliases":[],"length_aa":745,"mass_kda":87.0,"function":"Core component of multiple cullin-RING-based ECS (ElonginB/C-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of target proteins (PubMed:11384984, PubMed:26138980, PubMed:29775578, PubMed:29779948, PubMed:37844242, PubMed:38326650). CUL2 serves as a rigid scaffold in the complex and may contribute to catalysis through positioning of the substrate and the E2 ubiquitin-conjugating enzyme (PubMed:10973499, PubMed:11384984, PubMed:12609982, PubMed:24076655, PubMed:9122164, PubMed:37844242, PubMed:38326650). The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1 (PubMed:12609982, PubMed:24076655, PubMed:27565346, PubMed:38326650). The functional specificity of the ECS complex depends on the substrate recognition component (PubMed:10973499, PubMed:26138980, PubMed:29775578, PubMed:29779948, PubMed:9122164, PubMed:38326650). ECS(VHL) mediates the ubiquitination of hypoxia-inducible factor (HIF) (PubMed:10973499, PubMed:9122164). A number of ECS complexes (containing either KLHDC2, KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:26138980, PubMed:29775578, PubMed:29779948, PubMed:37844242). ECS complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed:27565346). ECS(LRR1) ubiquitinates MCM7 and promotes CMG replisome disassembly by VCP and chromatin extraction during S-phase (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13617/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CUL2","classification":"Common Essential","n_dependent_lines":830,"n_total_lines":1208,"dependency_fraction":0.6870860927152318},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CUL2","total_profiled":1310},"omim":[{"mim_id":"620077","title":"PROTEIN-L-ISOASPARTATE (D-ASPARTATE) O-METHYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 2; PCMTD2","url":"https://www.omim.org/entry/620077"},{"mim_id":"618675","title":"ZYG11 FAMILY, MEMBER A, CELL CYCLE REGULATOR; ZYG11A","url":"https://www.omim.org/entry/618675"},{"mim_id":"618673","title":"ZYG11 FAMILY, MEMBER B, CELL CYCLE REGULATOR; ZYG11B","url":"https://www.omim.org/entry/618673"},{"mim_id":"617764","title":"ZYG11-RELATED CELL CYCLE REGULATOR; ZER1","url":"https://www.omim.org/entry/617764"},{"mim_id":"616704","title":"COMM DOMAIN-CONTAINING PROTEIN 10; COMMD10","url":"https://www.omim.org/entry/616704"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CUL2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q13617","domains":[{"cath_id":"1.20.1310.10","chopping":"386-546","consensus_level":"medium","plddt":86.4869,"start":386,"end":546},{"cath_id":"3.30.230.130","chopping":"556-657","consensus_level":"high","plddt":85.6891,"start":556,"end":657},{"cath_id":"1.10.10.10","chopping":"661-742","consensus_level":"high","plddt":89.6444,"start":661,"end":742}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13617","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13617-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13617-F1-predicted_aligned_error_v6.png","plddt_mean":85.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CUL2","jax_strain_url":"https://www.jax.org/strain/search?query=CUL2"},"sequence":{"accession":"Q13617","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13617.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13617/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13617"}},"corpus_meta":[{"pmid":"9122164","id":"PMC_9122164","title":"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9122164","citation_count":417,"is_preprint":false},{"pmid":"15601820","id":"PMC_15601820","title":"VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15601820","citation_count":411,"is_preprint":false},{"pmid":"9447969","id":"PMC_9447969","title":"Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9447969","citation_count":320,"is_preprint":false},{"pmid":"29844124","id":"PMC_29844124","title":"Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29844124","citation_count":269,"is_preprint":false},{"pmid":"10579999","id":"PMC_10579999","title":"The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.","date":"1999","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10579999","citation_count":238,"is_preprint":false},{"pmid":"18187417","id":"PMC_18187417","title":"Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18187417","citation_count":168,"is_preprint":false},{"pmid":"28591624","id":"PMC_28591624","title":"Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex.","date":"2017","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/28591624","citation_count":122,"is_preprint":false},{"pmid":"17609115","id":"PMC_17609115","title":"A CUL-2 ubiquitin ligase containing three FEM proteins degrades TRA-1 to regulate C. elegans sex determination.","date":"2007","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/17609115","citation_count":122,"is_preprint":false},{"pmid":"10587644","id":"PMC_10587644","title":"CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in Caenorhabditis elegans.","date":"1999","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10587644","citation_count":112,"is_preprint":false},{"pmid":"15215208","id":"PMC_15215208","title":"Zyg-11 and cul-2 regulate progression through meiosis II and polarity establishment in C. elegans.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15215208","citation_count":108,"is_preprint":false},{"pmid":"15215209","id":"PMC_15215209","title":"CUL-2 and ZYG-11 promote meiotic anaphase II and the proper placement of the anterior-posterior axis in C. elegans.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15215209","citation_count":77,"is_preprint":false},{"pmid":"12149480","id":"PMC_12149480","title":"Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12149480","citation_count":75,"is_preprint":false},{"pmid":"25661653","id":"PMC_25661653","title":"Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25661653","citation_count":74,"is_preprint":false},{"pmid":"35650603","id":"PMC_35650603","title":"CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35650603","citation_count":62,"is_preprint":false},{"pmid":"21822215","id":"PMC_21822215","title":"The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21822215","citation_count":60,"is_preprint":false},{"pmid":"33398168","id":"PMC_33398168","title":"Molecular basis for arginine C-terminal degron recognition by Cul2FEM1 E3 ligase.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33398168","citation_count":50,"is_preprint":false},{"pmid":"17304241","id":"PMC_17304241","title":"The Caenorhabditis elegans cell-cycle regulator ZYG-11 defines a conserved family of CUL-2 complex components.","date":"2007","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/17304241","citation_count":47,"is_preprint":false},{"pmid":"12647059","id":"PMC_12647059","title":"Genetic and morphological characterization of the barley uniculm2 (cul2) mutant.","date":"2003","source":"TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik","url":"https://pubmed.ncbi.nlm.nih.gov/12647059","citation_count":43,"is_preprint":false},{"pmid":"10807693","id":"PMC_10807693","title":"Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.","date":"2000","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10807693","citation_count":42,"is_preprint":false},{"pmid":"17132228","id":"PMC_17132228","title":"Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17132228","citation_count":34,"is_preprint":false},{"pmid":"33590678","id":"PMC_33590678","title":"CUL2LRR1 , TRAIP and p97 control CMG helicase disassembly in the mammalian cell cycle.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33590678","citation_count":32,"is_preprint":false},{"pmid":"35027503","id":"PMC_35027503","title":"Circular RNA CUL2 regulates the development of colorectal cancer by modulating apoptosis and autophagy via miR-208a-3p/PPP6C.","date":"2022","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/35027503","citation_count":31,"is_preprint":false},{"pmid":"26751167","id":"PMC_26751167","title":"CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26751167","citation_count":30,"is_preprint":false},{"pmid":"36126167","id":"PMC_36126167","title":"NLRC5 restricts dengue virus infection by promoting the autophagic degradation of viral NS3 through E3 ligase CUL2 (cullin 2).","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36126167","citation_count":30,"is_preprint":false},{"pmid":"12175939","id":"PMC_12175939","title":"Study on the interactions between CuL(2) and Morin with DNA.","date":"2002","source":"Journal of inorganic biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12175939","citation_count":29,"is_preprint":false},{"pmid":"33333053","id":"PMC_33333053","title":"microRNA-322/424 promotes liver fibrosis by regulating angiogenesis through targeting CUL2/HIF-1α pathway.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33333053","citation_count":27,"is_preprint":false},{"pmid":"18372249","id":"PMC_18372249","title":"CUL2 is required for the activity of hypoxia-inducible factor and vasculogenesis.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18372249","citation_count":26,"is_preprint":false},{"pmid":"32742484","id":"PMC_32742484","title":"MicroRNA-154-5p regulates the HPV16 E7-pRb pathway in Cervical Carcinogenesis by targeting CUL2.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32742484","citation_count":22,"is_preprint":false},{"pmid":"27153550","id":"PMC_27153550","title":"CUL2 overexpression driven by CUL2/E2F1/miR-424 regulatory loop promotes HPV16 E7 induced cervical carcinogenesis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27153550","citation_count":21,"is_preprint":false},{"pmid":"10441001","id":"PMC_10441001","title":"Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.","date":"1999","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10441001","citation_count":18,"is_preprint":false},{"pmid":"20078552","id":"PMC_20078552","title":"Mutational analysis of hypoxia-related genes HIF1alpha and CUL2 in common human cancers.","date":"2009","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/20078552","citation_count":17,"is_preprint":false},{"pmid":"20712528","id":"PMC_20712528","title":"CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer.","date":"2010","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/20712528","citation_count":17,"is_preprint":false},{"pmid":"15966899","id":"PMC_15966899","title":"Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex.","date":"2005","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/15966899","citation_count":16,"is_preprint":false},{"pmid":"18502413","id":"PMC_18502413","title":"PAR-6 levels are regulated by NOS-3 in a CUL-2 dependent manner in Caenorhabditiselegans.","date":"2008","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18502413","citation_count":16,"is_preprint":false},{"pmid":"35068326","id":"PMC_35068326","title":"Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35068326","citation_count":14,"is_preprint":false},{"pmid":"34045610","id":"PMC_34045610","title":"Expression and purification of functional recombinant CUL2•RBX1 from E. coli.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34045610","citation_count":11,"is_preprint":false},{"pmid":"36423673","id":"PMC_36423673","title":"E3 ligase Cul2 mediates Drosophila early germ cell differentiation through targeting Bam.","date":"2022","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36423673","citation_count":11,"is_preprint":false},{"pmid":"34031216","id":"PMC_34031216","title":"LINC00997/MicroRNA 574-3p/CUL2 Promotes Cervical Cancer Development via Mitogen-Activated Protein Kinase Signaling.","date":"2021","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34031216","citation_count":10,"is_preprint":false},{"pmid":"18365106","id":"PMC_18365106","title":"Synthesis, characterization and antitumor activity of copper(II) complexes, [CuL2] [HL1-3=N,N-diethyl-N'-(R-benzoyl)thiourea (R=H, o-Cl and p-NO2)].","date":"2005","source":"Bioinorganic chemistry and applications","url":"https://pubmed.ncbi.nlm.nih.gov/18365106","citation_count":10,"is_preprint":false},{"pmid":"10487688","id":"PMC_10487688","title":"Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10487688","citation_count":8,"is_preprint":false},{"pmid":"34655362","id":"PMC_34655362","title":"MicroRNA-574-3p Regulates HIF-α Isoforms Promoting Gastric Cancer Epithelial-Mesenchymal Transition via Targeting CUL2.","date":"2021","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34655362","citation_count":7,"is_preprint":false},{"pmid":"34717191","id":"PMC_34717191","title":"Immunoexpression of HSPA9 and CUL2 in prostatic tissue and adenocarcinoma.","date":"2021","source":"Annals of diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34717191","citation_count":5,"is_preprint":false},{"pmid":"40411782","id":"PMC_40411782","title":"USP37 protects mammalian cells during DNA replication stress by counteracting CUL2LRR1 and TRAIP.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40411782","citation_count":4,"is_preprint":false},{"pmid":"38332149","id":"PMC_38332149","title":"PRAMEL7 and CUL2 decrease NuRD stability to establish ground-state pluripotency.","date":"2024","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/38332149","citation_count":4,"is_preprint":false},{"pmid":"40141268","id":"PMC_40141268","title":"Cul2 Is Essential for the Drosophila IMD Signaling-Mediated Antimicrobial Immune Defense.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40141268","citation_count":3,"is_preprint":false},{"pmid":"40413536","id":"PMC_40413536","title":"Identification and validation of USP15 and CUL2 as ubiquitination related biomarker in chronic obstructive pulmonary disease.","date":"2025","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/40413536","citation_count":2,"is_preprint":false},{"pmid":"41402811","id":"PMC_41402811","title":"CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/41402811","citation_count":0,"is_preprint":false},{"pmid":"41932528","id":"PMC_41932528","title":"Dysregulation of the CUL2-Sirt2 axis exacerbates lung epithelial barrier injury in Staphylococcus aureus-induced pneumonia.","date":"2026","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/41932528","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":25364,"output_tokens":6781,"usd":0.088903,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15623,"output_tokens":5652,"usd":0.109707,"stage2_stop_reason":"end_turn"},"total_usd":0.19861,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CUL2 (Hs-CUL-2) specifically associates with the trimeric pVHL-Elongin B-Elongin C (VBC) complex both in vitro and in vivo; this association is strictly dependent on the integrity of the trimeric VBC complex, and ~70% of cancer-predisposing VHL mutations disrupt this interaction. CUL2 is a cytosolic protein that can be translocated to the nucleus by pVHL.\",\n      \"method\": \"Co-immunoprecipitation in vivo and in vitro binding assays; immunofluorescence for localization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP in vivo and in vitro, multiple VHL mutants tested, replicated by subsequent studies\",\n      \"pmids\": [\"9122164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"pVHL binds to human CUL2 via Elongin C; pVHL-CUL2 complexes exist in native cells, and pVHL mutants unable to bind Elongin C/CUL2 are likewise unable to inhibit accumulation of hypoxia-inducible mRNAs under normoxia, placing CUL2 in the VHL ubiquitin ligase pathway controlling HIF target gene expression.\",\n      \"method\": \"Co-immunoprecipitation; chromatographic co-purification; functional assays with VHL mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus chromatographic co-purification plus functional mutant analysis, replicated across labs\",\n      \"pmids\": [\"9447969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The Cul2/Rbx1 module (alongside Cdc53/Rbx1 of SCF) activates ubiquitin conjugation to target proteins via E2 enzymes Cdc34 and Ubc5, and also activates conjugation of the ubiquitin-like protein Rub1 to Cul2 itself via the dedicated E2 Ubc12; Rbx1 is the common component mediating both ubiquitin and Rub1 modification.\",\n      \"method\": \"In vitro ubiquitination and Rub1-conjugation assays with reconstituted Cul2/Rbx1 module\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay demonstrating enzymatic activity, multiple substrates and E2 enzymes tested in a single rigorous study\",\n      \"pmids\": [\"10579999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In C. elegans, cul-2 is required at two distinct cell-cycle points: the G1-to-S-phase transition and mitotic chromosome condensation. Loss of cul-2 causes G1 arrest correlating with accumulation of the CDK inhibitor CKI-1, and prevents mitotic chromosome condensation, leading to unequal DNA segregation and chromosome bridging.\",\n      \"method\": \"Genetic loss-of-function (cul-2 mutants) in C. elegans with cell-cycle phenotype readouts; CKI-1 protein level analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined cellular phenotypes and molecular correlate (CKI-1 accumulation), replicated in subsequent C. elegans work\",\n      \"pmids\": [\"10587644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VHL-box proteins (containing a BC box plus a downstream Cul2 box) specifically interact with Cul2-Rbx1, whereas SOCS-box proteins (BC box plus Cul5 box) interact with Cul5-Rbx2. Domain-swapping analyses showed Cul2 and Cul5 box sequences determine this specificity. RNAi knockdown of Cul2-Rbx1 inhibited VHL-mediated degradation of HIF-2α, while knockdown of Cul5-Rbx2 did not.\",\n      \"method\": \"Co-immunoprecipitation of endogenous complexes; domain-swap mutagenesis; RNAi knockdown with HIF-2α degradation readout\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis, Co-IP, and RNAi functional assay in a single study; defines molecular determinant of Cul2 vs. Cul5 specificity\",\n      \"pmids\": [\"15601820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZYG-11 and CUL-2 promote the metaphase-to-anaphase transition and M phase exit at meiosis II in C. elegans by acting together in a CUL-2-based E3 ligase; loss of either gene causes accumulation of cyclin CYB-3, delayed meiotic exit, and inverted embryonic polarity (PAR proteins, P granules, pronuclear migration).\",\n      \"method\": \"RNAi loss-of-function in C. elegans; analysis of cyclin B levels, PAR protein localization, cell-cycle progression\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with molecular substrate (CYB-3) and polarity readouts, replicated in parallel study (PMID:15215209)\",\n      \"pmids\": [\"15215208\", \"15215209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CUL-2 is required for degradation of cyclin B1 during C. elegans meiosis; loss of cul-2 delays or abolishes meiotic anaphase II (not anaphase I) without preventing cohesin REC-8 removal or sister chromatid separation, indicating a specific defect in chromosome movement. Partial rescue of meiotic delay by cyclin B1 inactivation confirms cyclin B1 is a CUL-2 target.\",\n      \"method\": \"Genetic loss-of-function with epistasis (cul-2 mutant × cyclin B1 inactivation); cytological analysis of chromosome behavior and REC-8 localization\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with substrate-level rescue, parallel independent study (PMID:15215208)\",\n      \"pmids\": [\"15215209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NEDD8 modification (neddylation) of Cul2 is required for activation of the ECV (ElonginBC-Cul2-VHL) E3 ubiquitin ligase. Oxygen-dependent recognition of HIFα by VHL triggers Rbx1-dependent neddylation of Cul2, which preferentially engages the E2 ubiquitin-conjugating enzyme UbcH5a to ubiquitylate HIFα.\",\n      \"method\": \"Cell-based assays; manipulation of neddylation pathway; identification of E2 preference by biochemical assays\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based assay with mechanistic follow-up, single lab, two orthogonal approaches\",\n      \"pmids\": [\"17132228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In C. elegans, CUL-2-based ubiquitin ligase containing FEM-1 (substrate-recognition subunit), FEM-2, and FEM-3 (cofactors) degrades the Gli-family transcription factor TRA-1 to regulate sex determination. CUL-2 physically associates with FEM-1 and TRA-1 in vivo; when FEM proteins are expressed in human cells, they interact with human CUL2 and induce proteasome-dependent TRA-1 degradation.\",\n      \"method\": \"Co-immunoprecipitation in vivo; genetic epistasis; proteasome inhibitor experiments; heterologous expression in human cells\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, and cross-species functional validation in a single rigorous study\",\n      \"pmids\": [\"17609115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZYG-11 is the substrate-recognition subunit for a CUL-2-based E3 ubiquitin ligase complex in C. elegans; ZYG-11 interacts with CUL-2 in vivo and binds the adaptor protein Elongin C via a nematode variant of the VHL-box motif. Members of the ZYG11 gene family across metazoa (including humans) are conserved CUL2-based ubiquitin ligase components.\",\n      \"method\": \"Co-immunoprecipitation in vivo; sequence/domain analysis; conservation mapping\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP in vivo plus domain analysis, single lab\",\n      \"pmids\": [\"17304241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CUL-2/FEM-1 ubiquitin ligase (CBC(FEM-1)) regulates PAR-6 protein levels in C. elegans; PAR-6 physically interacts with FEM-1, and CUL-2 is required for degradation of PAR-6 to control cell polarity.\",\n      \"method\": \"Genetic epistasis (nos-3; par-2 suppression); Co-immunoprecipitation (PAR-6 with FEM-1); protein level analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis combined with Co-IP, single lab\",\n      \"pmids\": [\"18502413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CUL2 characterization of Cul2-box sequences: the spacing between BC-box and Cullin-box is flexible (3 to ~80 aa); the LPPhiP motif conserved in most Cul5-boxes is also compatible with Cul2 interaction; residues conserved in the Cul2-box are a subset of those conserved in the Cul5-box. These structure-function studies define the rules for assembly of BC-box proteins with Cul2-Rbx1 versus Cul5-Rbx2 modules.\",\n      \"method\": \"Purification of BC-box protein complexes; structure-function/mutagenesis analysis; mass spectrometry-based interactome\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical reconstitution combined with mutagenesis, single lab\",\n      \"pmids\": [\"18187417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CUL2 is required for HIF transcriptional activity in a manner distinct from its known role in HIFα degradation: CUL2 siRNA inhibits HIFα-mediated VEGF promoter activation and reduces ARNT expression; ectopic ARNT rescues HIF activity, placing CUL2 upstream of ARNT. In VHL-null cells (786-O), Cul2 siRNA still suppresses ARNT and VEGF, indicating this function is VHL-independent. In zebrafish, zCul2 morpholino blocks embryonic vasculogenesis.\",\n      \"method\": \"siRNA knockdown with VEGF promoter reporter assay; Western blot for ARNT; zebrafish morpholino knockdown with vasculogenesis readout\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi loss-of-function with multiple readouts (reporter assay, protein levels, in vivo vasculogenesis), single lab\",\n      \"pmids\": [\"18372249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PRAME (preferentially expressed antigen of melanoma) is a substrate-recognition subunit of a Cul2-based E3 ubiquitin ligase. PRAME can be recruited to DNA in vitro and is specifically enriched genome-wide at transcriptionally active NFY-bound promoters and enhancers.\",\n      \"method\": \"Protein complex purification (affinity purification/mass spectrometry); chromatin immunoprecipitation (genome-wide); in vitro DNA binding\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — AP-MS identification plus ChIP-seq, single lab, two orthogonal methods\",\n      \"pmids\": [\"21822215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of VHL bound to the Cul2 N-terminal domain, Elongin B, and Elongin C reveals that Cul2 interacts with both the VHL BC box and cullin box and a novel EloC site. Cullin selectivity is influenced by distinct electrostatic interactions between cullin and substrate receptor.\",\n      \"method\": \"X-ray crystallography; comparative structural analysis with other cullin E3 ligase structures\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with structural comparison defining molecular basis of cullin selectivity, single lab but rigorous structural method\",\n      \"pmids\": [\"25661653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CUL2 E3 ubiquitin ligase (with VHL as substrate-binding component) recognizes misfolded/fragmented TDP-43 at Glu246 in RRM2 and mediates its degradation. Excess VHL paradoxically stabilizes TDP-43 and promotes inclusion formation at the juxtanuclear protein quality control center. CUL2 also ubiquitylates mutant SOD1.\",\n      \"method\": \"Recombinant protein structural fragility assay; site-directed identification of VHL recognition residue (Glu246); cell-based overexpression/knockdown; immunohistochemistry of ALS spinal cord\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant protein assay plus cell-based mechanistic study, single lab, multiple substrates\",\n      \"pmids\": [\"26751167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the full pentameric CRL2VHL complex (Cul2-Rbx1-EloB-EloC-pVHL) reveals a closed conformation of full-length Cul2 and a new Rbx1 pose in trajectory from closed to open. Hotspot residues at the Cul2/pVHL-EloBC interface are characterized; mutations at specific positions create a selectivity switch between Cul2 and Cul5 recognition.\",\n      \"method\": \"X-ray crystallography; thermodynamic binding analyses (ITC/SPR); mutagenesis of selectivity determinants\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus biophysical binding thermodynamics plus mutagenesis in one rigorous study\",\n      \"pmids\": [\"28591624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CUL2LRR1 ubiquitin ligase is required for ubiquitylation of the CMG helicase MCM7 subunit during S-phase in mammalian cells, leading to replisome disassembly by the p97 ATPase. A second mitotic pathway of CMG disassembly is dependent on the TRAIP ubiquitin ligase.\",\n      \"method\": \"Loss-of-function studies in mouse embryonic stem cells; ubiquitylation assays; chromatin fractionation\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined molecular phenotype (MCM7 ubiquitylation, replisome disassembly) in mammalian cells, rigorous controls\",\n      \"pmids\": [\"33590678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of FEM1A, FEM1B, and FEM1C (substrate adapters of CRL2) in complex with Arg/C-degron-bearing substrates reveal the molecular mechanism of C-terminal arginine degron recognition. FEM1A/C and FEM1B selectively target distinct subclasses of Arg/C-degrons, providing the structural basis for substrate selectivity in CRL2FEM1 complexes.\",\n      \"method\": \"X-ray crystallography; in vitro binding assays; global protein stability (GPS) analysis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with multiple FEM1 paralogs plus binding assays plus functional proteome-wide GPS analysis in one study\",\n      \"pmids\": [\"33398168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Functional recombinant CUL2·RBX1 complex purified from E. coli is enzymatically active in transferring ubiquitin (and ubiquitin-like proteins) to substrates in vitro and can bind substrate receptor modules (e.g., VHL-EloBC for HIF1α ubiquitination).\",\n      \"method\": \"Recombinant protein expression/purification; in vitro ubiquitination assay; substrate receptor binding assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of enzymatic activity, methodological paper, single lab\",\n      \"pmids\": [\"34045610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NLRC5 recruits CUL2 to catalyze K48-linked poly-ubiquitination of the dengue virus NS3 protease domain, targeting NS3 for selective autophagic degradation via the cargo receptor TOLLIP, thereby restricting DENV infection.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays (K48-linkage specific); NLRC5/CUL2 knockdown/knockout with viral replication readout; autophagy flux assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination linkage analysis plus loss-of-function, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36126167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Drosophila Cul2 mediates ubiquitination of Bam (bag-of-marbles) protein at multiple lysine residues in its C-terminal region, promoting Bam turnover; genetic evidence shows Cul2-mediated Bam ubiquitination is essential for germline stem cell maintenance and proper germ cell differentiation.\",\n      \"method\": \"Ubiquitination assays; genetic epistasis in Drosophila; site-directed mutagenesis of Bam lysine residues\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo ubiquitination assay plus genetic epistasis in Drosophila, single lab\",\n      \"pmids\": [\"36423673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRAMEL7 associates with CUL2 and recruits it to chromatin; PRAMEL7-CUL2 targets NuRD complex components for proteasomal degradation, decreasing NuRD stability and its promoter association, thereby antagonizing NuRD-mediated repression of pluripotency genes and establishing ground-state pluripotency.\",\n      \"method\": \"Co-immunoprecipitation; chromatin fractionation; proteasome inhibitor experiments; loss-of-function rescue assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, chromatin fractionation, and functional rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38332149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP37 deubiquitylase binds the CMG helicase (via CDC45) at replication forks and counteracts CUL2LRR1-mediated ubiquitylation of CMG, preventing premature replisome disassembly. Structure-guided mutations displacing USP37 from CMG sensitize cells to DNA synthesis defects; depletion of CUL2LRR1 suppresses this sensitivity.\",\n      \"method\": \"Co-immunoprecipitation (USP37–CMG); structure-guided mutagenesis; genetic epistasis (USP37 mutant × CUL2LRR1 depletion); DNA damage sensitivity assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, structure-guided mutagenesis, and genetic epistasis in a single rigorous study\",\n      \"pmids\": [\"40411782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CUL2 mediates K48-linked ubiquitination of Sirt2, targeting it for proteasomal degradation; silencing CUL2 stabilizes Sirt2 protein levels, reduces NF-κB pathway activation, and preserves lung epithelial barrier protein expression (Occludin, Claudin-1, ZO-1) during S. aureus infection.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination linkage assay (K48-specific); CUL2 siRNA knockdown with Sirt2 protein level and NF-κB readouts; Western blot and immunofluorescence\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ubiquitination assay plus functional knockdown, single lab, single study\",\n      \"pmids\": [\"41932528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CUL2 competes with NRF2 for KEAP1 binding, preventing KEAP1-mediated NRF2 degradation and promoting NRF2 nuclear translocation; this CUL2-NRF2 axis suppresses ferroptosis and confers gemcitabine resistance in pancreatic cancer cells and xenografts.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation; proteasome inhibitor (MG132) assay; gain- and loss-of-function in vitro and xenograft studies; ferroptosis assays\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, fractionation, and functional rescue studies in vitro and in vivo, single lab\",\n      \"pmids\": [\"41402811\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CUL2 is the scaffold protein of a family of multisubunit Cullin-RING E3 ubiquitin ligases (CRL2s) in which it bridges Rbx1 (the RING-H2 catalytic subunit) to an Elongin B/C adaptor linked to variable substrate-recognition subunits (VHL, PRAME, FEM1A/B/C, LRR1, ZYG-11, PRAMEL7, and others) that determine substrate specificity; the NEDD8 modification of CUL2 by Rbx1 activates ubiquitin transfer, and substrate-receptor specificity for CUL2 versus CUL5 is encoded in short 'Cul2-box' or 'Cul5-box' sequences downstream of the BC-box, as defined structurally and by mutagenesis; functionally, CRL2s ubiquitylate substrates including HIF-1/2α (targeting them for oxygen-dependent proteasomal degradation), cyclin B1 (controlling meiotic progression), CMG-MCM7 (driving replisome disassembly at termination, counteracted by USP37), TRA-1 (sex determination in C. elegans), PAR-6 (cell polarity), misfolded TDP-43, dengue NS3, Sirt2, and NuRD components, positioning CUL2 as a central regulator of cell-cycle progression, embryonic polarity, DNA replication termination, hypoxia response, and proteostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CUL2 is the scaffold subunit of a family of multisubunit Cullin-RING E3 ubiquitin ligases (CRL2s) that direct substrate-specific ubiquitylation across cell-cycle control, hypoxia signaling, DNA replication, and proteostasis [#0, #4, #17]. It bridges the catalytic RING subunit Rbx1 to an Elongin B/Elongin C adaptor, which in turn docks variable substrate-recognition subunits via a BC box plus a downstream 'Cul2 box'; domain-swap and structural analyses establish that these short Cul2-box versus Cul5-box determinants encode whether a receptor assembles with Cul2-Rbx1 or Cul5-Rbx2 [#4, #11, #14, #16]. The reconstituted Cul2/Rbx1 module is enzymatically active, conjugating ubiquitin to substrates through E2 enzymes and accepting NEDD8/Rub1 modification on Cul2 itself; this neddylation is required to activate the assembled ligase for substrate ubiquitylation [#2, #7, #19]. Through the VHL substrate receptor, CRL2 targets HIF-α for oxygen-dependent proteasomal degradation, and disruption of the Cul2-VHL interaction accounts for a large fraction of cancer-predisposing VHL mutations [#0, #1, #4]. Distinct substrate receptors route CUL2 to functionally diverse targets: ZYG-11 and FEM-1 direct degradation of cyclin B1, the sex-determining factor TRA-1, and the polarity protein PAR-6 to govern meiotic progression, sex determination, and embryonic polarity [#5, #6, #8, #10]; LRR1 directs ubiquitylation of the CMG helicase subunit MCM7 to drive replisome disassembly at replication termination, a reaction opposed by the deubiquitylase USP37 [#17, #23]; and FEM1 paralogs recognize C-terminal arginine (Arg/C) degrons [#18]. Additional receptor-defined activities include PRAME- and PRAMEL7-directed chromatin functions that regulate transcription and pluripotency, and degradation of misfolded TDP-43, viral dengue NS3, and Sirt2 [#13, #22, #15, #20, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established CUL2 as a physical component of the VHL tumor-suppressor complex, linking a cullin to human cancer predisposition for the first time.\",\n      \"evidence\": \"in vivo and in vitro Co-IP showing trimeric VBC-dependent association, with disease-mutant analysis\",\n      \"pmids\": [\"9122164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the enzymatic output of the complex\", \"Did not identify substrates\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Placed CUL2 functionally in the VHL ubiquitin ligase pathway controlling hypoxia-inducible gene expression by mapping the pVHL-CUL2 bridge through Elongin C.\",\n      \"evidence\": \"Co-IP, chromatographic co-purification, and VHL mutant functional assays in native cells\",\n      \"pmids\": [\"9447969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitylation of HIF substrate not yet demonstrated\", \"Did not address oxygen-sensing mechanism\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated that the Cul2/Rbx1 module is an active ubiquitin-conjugating machine and is itself modified by the ubiquitin-like protein Rub1, defining its enzymatic core.\",\n      \"evidence\": \"in vitro reconstituted ubiquitination and Rub1-conjugation assays with multiple E2 enzymes\",\n      \"pmids\": [\"10579999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates not identified in this assay\", \"Role of neddylation in activation not yet shown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Connected CUL2 to in vivo cell-cycle control, showing it acts at the G1/S transition and in mitotic chromosome condensation via CDK-inhibitor turnover.\",\n      \"evidence\": \"C. elegans cul-2 loss-of-function with cell-cycle phenotypes and CKI-1 protein-level readout\",\n      \"pmids\": [\"10587644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish CKI-1 as a direct ubiquitylation substrate\", \"Substrate receptor for cell-cycle role unidentified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the molecular code for cullin selectivity, showing Cul2-box versus Cul5-box sequences determine whether a BC-box receptor assembles with Cul2-Rbx1 or Cul5-Rbx2, with functional consequences for HIF-2α degradation.\",\n      \"evidence\": \"endogenous Co-IP, domain-swap mutagenesis, and RNAi with HIF-2α degradation readout\",\n      \"pmids\": [\"15601820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of box recognition not yet resolved\", \"Did not catalog the full receptor repertoire\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified ZYG-11 as a CUL-2 substrate receptor driving meiotic cyclin B turnover and showed CUL-2 controls meiotic exit and embryonic polarity, expanding its substrate range beyond HIF.\",\n      \"evidence\": \"C. elegans RNAi with cyclin B (CYB-3) levels, PAR-protein localization, and epistasis including cyclin B1 inactivation rescue\",\n      \"pmids\": [\"15215208\", \"15215209\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitylation of cyclin B by CUL-2 not biochemically reconstituted\", \"Mammalian conservation of this meiotic role untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed that NEDD8 modification of Cul2 activates the ECV ligase and that HIFα recognition triggers Rbx1-dependent neddylation and a specific E2 (UbcH5a) for substrate ubiquitylation, defining the activation switch.\",\n      \"evidence\": \"cell-based neddylation pathway manipulation and biochemical E2-preference assays\",\n      \"pmids\": [\"17132228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Quantitative kinetics of neddylation-coupled activation not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established CUL-2 substrate receptors FEM-1 and ZYG-11 as the specificity determinants targeting the Gli factor TRA-1 for sex determination, with cross-species validation in human cells.\",\n      \"evidence\": \"Co-IP, genetic epistasis, proteasome inhibition, and heterologous expression in human cells; VHL-box motif mapping for ZYG-11\",\n      \"pmids\": [\"17609115\", \"17304241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human orthologous substrate of ZYG11/FEM not identified\", \"Direct ubiquitylation site on TRA-1 not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended CRL2 receptor logic with detailed Cul2-box assembly rules and revealed a VHL-independent CUL2 role supporting HIF transcriptional activity through ARNT and vasculogenesis.\",\n      \"evidence\": \"biochemical complex purification with mutagenesis; siRNA with VEGF reporter, ARNT Westerns, and zebrafish morpholino vasculogenesis assay; PAR-6 Co-IP and epistasis\",\n      \"pmids\": [\"18187417\", \"18372249\", \"18502413\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CUL2 controls ARNT levels unresolved\", \"Single-lab findings for the VHL-independent transcriptional role\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified PRAME as a CUL2 substrate receptor with chromatin-targeting capacity, linking the ligase to transcriptional regulation at active promoters.\",\n      \"evidence\": \"affinity purification/mass spectrometry, genome-wide ChIP, and in vitro DNA binding\",\n      \"pmids\": [\"21822215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chromatin-associated ubiquitylation substrate of PRAME-CUL2 not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided the first structural view of how Cul2 engages VHL-EloBC, revealing BC-box, cullin-box, and a novel EloC contact site and electrostatic determinants of cullin selectivity.\",\n      \"evidence\": \"X-ray crystallography of the Cul2 N-terminal domain with VHL-EloB-EloC and comparative analysis\",\n      \"pmids\": [\"25661653\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length cullin conformation not captured\", \"Catalytic geometry with Rbx1 and substrate not visualized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved the full pentameric CRL2VHL architecture, capturing a closed Cul2 conformation and an intermediate Rbx1 pose, and pinpointed interface hotspots that act as a Cul2/Cul5 selectivity switch.\",\n      \"evidence\": \"X-ray crystallography with ITC/SPR binding thermodynamics and selectivity-determinant mutagenesis\",\n      \"pmids\": [\"28591624\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of the closed-to-open transition during catalysis not directly observed\", \"Substrate-bound ubiquitin-transfer state not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined CUL2LRR1 as the S-phase ligase that ubiquitylates the CMG subunit MCM7 to drive p97-mediated replisome disassembly at replication termination, distinct from a mitotic TRAIP pathway.\",\n      \"evidence\": \"loss-of-function in mouse ES cells, ubiquitylation assays, and chromatin fractionation\",\n      \"pmids\": [\"33590678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger that activates CUL2LRR1 at termination not fully defined\", \"Regulatory coupling to other termination factors unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established the structural basis of Arg/C-degron recognition by FEM1 paralog substrate adapters, defining how CRL2FEM1 complexes achieve degron-class selectivity, and confirmed in vitro enzymatic activity of recombinant Cul2-Rbx1.\",\n      \"evidence\": \"crystal structures of FEM1A/B/C with degron substrates plus GPS proteome-wide analysis; recombinant Cul2-Rbx1 ubiquitination assays\",\n      \"pmids\": [\"33398168\", \"34045610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological Arg/C-degron substrates for each FEM1 paralog incompletely cataloged\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Broadened CUL2 function into antiviral immunity and germline differentiation through ubiquitylation of dengue NS3 and Drosophila Bam.\",\n      \"evidence\": \"Co-IP, K48-linkage ubiquitination assays, and loss-of-function with viral replication readouts; Drosophila genetic epistasis with Bam lysine mutagenesis\",\n      \"pmids\": [\"36126167\", \"36423673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate receptor mediating NS3 and Bam recognition not fully defined\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified PRAMEL7 as a CUL2 receptor that degrades NuRD components to antagonize repression of pluripotency genes, linking CUL2 to ground-state pluripotency.\",\n      \"evidence\": \"Co-IP, chromatin fractionation, proteasome inhibition, and loss-of-function rescue\",\n      \"pmids\": [\"38332149\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ubiquitylation sites on NuRD subunits not mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Refined replication-termination control by showing USP37 deubiquitylates CMG to oppose CUL2LRR1 and prevent premature replisome disassembly, and added Sirt2 and a KEAP1-NRF2 axis to the CUL2 repertoire in infection and cancer.\",\n      \"evidence\": \"USP37-CMG Co-IP, structure-guided mutagenesis, and CUL2LRR1-depletion epistasis; K48 ubiquitination and knockdown assays for Sirt2; Co-IP, fractionation, and ferroptosis/xenograft assays for NRF2\",\n      \"pmids\": [\"40411782\", \"41932528\", \"41402811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the KEAP1-NRF2 competition reflects ligase activity or non-catalytic sequestration not resolved\", \"Substrate receptors for Sirt2 degradation not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full mammalian substrate-receptor repertoire and the in vivo physiological substrate set for many human CRL2 complexes (e.g., ZYG11, PRAME) remain to be comprehensively defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Human orthologous substrates for several non-VHL receptors uncharacterized\", \"Regulation of receptor exchange on the shared Cul2 scaffold not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 7, 17, 19, 20, 24]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [2, 4, 18, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 14, 16]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [14, 16, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 13, 22]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [13, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 7, 19]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 4, 12]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [17, 23]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 5, 6]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 10, 22]}\n    ],\n    \"complexes\": [\n      \"CRL2 (Cullin2-RING E3 ubiquitin ligase)\",\n      \"CRL2-VHL (ElonginBC-Cul2-VHL / ECV)\",\n      \"CRL2-LRR1\",\n      \"CRL2-FEM1\"\n    ],\n    \"partners\": [\n      \"RBX1\",\n      \"VHL\",\n      \"Elongin C (TCEB1)\",\n      \"Elongin B (TCEB2)\",\n      \"ZYG-11\",\n      \"FEM-1\",\n      \"LRR1\",\n      \"PRAME\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}